Target intelligence / Profile preview

Ripply transcriptional repressor 2 (RIPPLY2)

Target
RIPPLY2
Molecular classification
Transcriptional repressor, Nuclear protein, Transcription factor (by family and function), Other: part of Ripply family
01

Overview

Ripply transcriptional repressor 2 (RIPPLY2) is a nuclear protein and member of the Ripply family involved in vertebrate somitogenesis and segmentation of the axial skeleton. RIPPLY2 contains a WRPW tetrapeptide motif, essential for interaction with the transcriptional co-repressor Groucho, and a C-terminal homology domain critical for its function. RIPPLY2 modulates transcription of T-box family transcription factors, such as Tbx6, often by recruiting the 26S proteasome complex to degrade these proteins in a highly tissue- and context-specific manner, especially in presomitic mesoderm (PSM) cells. Mutations or loss of RIPPLY2 disrupt normal somite formation and patterning, leading to conditions such as spondylocostal dysostosis. Though mechanistically important in embryogenesis, RIPPLY2 is not currently recognized as a clinical drug target, nor is it associated with known pharmacological agents, mechanisms, or safety concerns in a therapeutic setting

Other names
Protein ripply2C6orf159SCDO6dJ237I15.1ripply2 homologRIPP2
02

Mechanism of action

Not applicable. No drugs known to target RIPPLY2

03

Biological functions

Somitogenesis (formation of somites during vertebrate development)Segmentation of axial skeletonEstablishment of rostrocaudal polarity in somitesTranscriptional repression through protein-protein interactions (notably with T-box transcription factors and Groucho family members)Protein degradation: recruits proteasome to degrade specific transcription factors in a regulated, tissue-specific manner
04

Disease associations

Spondylocostal dysostosis 6, autosomal recessiveAbnormal axial skeleton segmentation (defects in vertebral column formation)
05

Safety considerations

None directly related to clinical modulation. Knockout and mutations in RIPPLY2 cause embryonic lethality and skeletal defects, indicating essential roles in development

Beyond the preview

Go deeper on Ripply transcriptional repressor 2 (RIPPLY2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ripply transcriptional repressor 2 (RIPPLY2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call